#Point-Of-Care Diagnostics Industry Report

[jcsmicasereports]

Trends in incidence of COVID 19 based on performed Rapid Antigen Test by Piratheep kumar.R in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

The COVID 19 outbreak represents a historically unprecedented pandemic, particularly dangerous and potentially lethal for elderly population. The biological differences in the immune systems between men and women exist which may impact our ability to fight an infection including SARS-2-CoV-2. Men tended to develop more symptomatic and serious disease than women, according to the clinical classification of severity. Age-related changes in the immune system are also different between sexes and there is a marked association between morbidity/mortality and advanced age in COVID-19. This is a single-center, retrospective, data oriented study performed at the private hospital, in Central Province, Sri Lanka. The data of the patients who performed the Rapid Antigen Test (RAT) to know whether they have infected by SARS-CoV-2 or not, were taken for analysis. Test performed date, age, sex, number of positive and negative cases, number of male and female patients were extracted. Finally the data were analyzed in simple statistical method according to the objective of the study. Totally 642 patients performed RAT within the period of one month from 11.08.2021 to 11.09.2021. Among them 426 (66.35%) are male and 216 (33.64%) are female. 20.4% (n=131) of male obtained positive result among the total male population (n=426). Likewise 11.4% (n=73) of female obtained positive result among the total male population (n=216).  Large number of positive cases was observed (34.89%) between the age group of 31-40 years in both sexes. The age group of 21-30 and 41-50 years also were shared the almost same percentage (17.13% & 17.75). The large number of positive male patients observed among the age group of 41-50 years. Almost same number of patients was observed in the age group of 21-30 and 31-40. The least number of positive cases (0.7% and 0.9%) observed almost in 0-10 and 81-90 years. When considering the females, large number of positive female patients observed among the age group of 31-40 years.

Key words: Rapid Antigen Test, Covid-19, SARS-CoV-2

Introduction

A rapid antigen test (RAT) or rapid antigen detection test (RADT), is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence of an antigen. It is used to detect SARS-CoV-2 that cause COVID-19. This test is one of the type of lateral flow tests that detect protein, differentiate it from other medical tests such as antibody tests or nucleic acid tests, of either laboratory or point-of-care types. Generally 5 to 30 minutes only will take to get result and, require minimal training or infrastructure, and cost effective (1).

Sri Lanka was extremely vulnerable to the spread of COVID-19 because of its thriving tourism industry and large expatriate population. Sri Lanka almost managed two waves of Covid-19 pandemic well, but has been facing difficulties to control the third wave. The Sri Lankan government has executed stern actions to control the disease including island-wide travel restrictions. The government has been working with its development partners to take necessary action to mobilize resources to respond to the health and economic challenges posed by the pandemic (2) (3).

The COVID 19 outbreak is dangerous and fatal for elderly population. Since the beginning of the actual SARS-CoV-2 outbreak there were an evident that older people were at higher risk to get the infection and develop a more severe with bad prognosis. The mean age of patients that died was 80 years. The majority of those who are infected, that have a self-limiting infection and do recover are younger. On the other hand, those who suffer with more severe disease require intensive care unit admission and finally pass away are older (4).

Sandoval.  M., et al mentioned that the number of patients who are affected by SARS-CoV-2 with more than 80 years of age is similar to that with 65–79 years. The mortality rate in very elderly was 37.5% and this percentage was significantly higher compared to that observed in elderly. Further their findings were suggested that the age is a fundamental risk factor for mortality (5).

Since February 2020, more than 27.7 million people in US have been diagnosed with Covid-19 (6). Rates of COVID-19 deaths have increased across the Southern US, among the Hispanic population, and among adults aged 25–44 years (7). Young adults are at increased risk of SARS-CoV-2 because of exposure in work, academic, and social settings. According to the several database of different health organizations young adult, aged 18-29, were confirmed Coid-19 (9).

Go to:Amid of coronavirus disease 2019 (Covid-19) pandemic, much emphasis was initially placed on the elderly or those who have preexisting health conditions such as obesity, hypertension, and diabetes as being at high risk of contracting and/or dying of Covid-19. But it is now becoming clear that being male is also a factor. The epidemiological findings reported across different parts of the world indicated higher morbidity and mortality in males than females. While it is still too early to determine why the gender gap is emerging, this article point to several possible factors such as higher expression of angiotensin-converting enzyme-2 (ACE 2; receptors for coronavirus) in male than female, sex-based immunological differences driven by sex hormone and X chromosome. Furthermore, a large part of this difference in number of deaths is caused by gender behavior (lifestyle), i.e., higher levels of smoking and drinking among men compared to women. Lastly, studies reported that women had more responsible attitude toward the Covid-19 pandemic than men. Irresponsible attitude among men reversibly affect their undertaking of preventive measures such as frequent handwashing, wearing of face mask, and stay at home orders.

The latest immunological study on the receptors for SARS-CoV-2 suggest that ACE2 receptors are responsible for SARS-CoV-2. According to the study by Lu and colleagues there are positive correlation of ACE2 expression and the infection of SARS-CoV (10). Based on the positive correlation between ACE 2 and coronavirus, different studies quantified the expression of ACE 2 proteins in human cells based on gender ethnicity and a study on the expression level and pattern of human ACE 2 using a single-cell RNA-sequencing analysis indicated that Asian males had higher expression of ACE 2 than female (11). Conversely, in establishing the expression of ACE 2 in the primary affected organ, a study conducted in Chinese population found that expression of ACE 2 in human lungs was extremely expressed in Asian male than female (12).

A study by Karnam and colleagues reveled that CD200-CD200R and sex are host factors that together determine the outcome of viral infection. Further a review on association between sex differences in immune responses stated that sex-based immunological differences contribute to variations in the susceptibility to infectious diseases and responses to vaccines in males and females (13). The concept of sex-based immunological differences driven by sex hormone and X chromosome has been well demonstrated via the animal study by Elgendy et al (14) (35). They were concluded the study that estrogen played big role in blocking some viral infection.

The biological differences in the immune systems between men and women may cause impact on fight for infection. Females are more resistant to infections than men and which mediated by certain factors including sex hormones. Further, women have more responsible attitude toward the Covid-19 pandemic than men such as frequent hand washing, wearing of face mask, and stay at home (15).

Most of the studies with Covid-19 patients indicate that males are mostly (more than 50%) affected than females (16) (17) (18). Although the deceased patients were significantly older than the patients who survived COVID-19, ages were comparable between males and females in both the deceased and the patients who survived (18).

A report in The Lancet and Global Health 5050 summary showed that sex-disaggregated data are essential to understanding the distribution of risk, infection and disease in the population, and the extent to which sex and gender affect clinical outcomes (19). The degree of outbreaks which affect men and women in different ways is an important to design the effective equitable policies and interventions (20). A systematic review and meta-analysis conducted to assess the sex difference in acquiring COVID-19 with 57 studies that revealed that the pooled prevalence of COVID-19 confirmed cases among men and women was 55% and 45% respectively (21). A study in Ontario, Canada showed that men were more likely to test positive (22) (23). In Pakistan 72% of COVID-19 cases were male (24). Moreover, the Global Health 5050 data showed that the number of COVID-19 confirmed cases and the death rate due to the disease are high among men in different countries. This might be because behavioral factors and roles which increase the risk of acquiring COVID-19 for men than women. (25) (26) (27).

Men mostly involved in several activities such as alcohol consumption, being involved in key activities during burial rites, and working in basic sectors and occupations that require them to continue being active, to work outside their homes and to interact with other people even during the containment phase. Therefore, men have increased level of exposure and high risk of getting COVID-19 (28) (29) (30).

Men tended to develop more symptomatic and serious disease than women, according to the clinical classification of severity (31). The same incidence also noticed during the previous coronavirus epidemics. Biological sex variation is said to be one of the reasons for the sex discrepancy in COVID-19 cases, severity and mortality (32) (33). Women are in general able to stand a strong immune response to infections and vaccinations (34).

The X chromosome is known to contain the largest number of immune-related genes in the whole genome. With their XX chromosome, women have a double copy of key immune genes compared with a single copy in XY in men. This showed that the reaction against infection would be contain both innate and adaptive immune response. Therefore the immune systems of females are generally more responsive than females and it indirectly reflects that women are able to challenge the coronavirus more effectively but this has not been proven (32).

Sex differences in the prevalence and outcomes of infectious diseases occur at all ages, with an overall higher burden of bacterial, viral, fungal and parasitic infections in human males (36) (37) (38) (39). The Hong Kong SARS-CoV-1 epidemic showed an age-adjusted relative mortality risk ratio of 1.62 (95% CI = 1.21, 2.16) for males (40). During the same outbreak in Singapore, male sex was associated with an odds ratio of 3.10 (95% CI = 1.64, 5.87; p ≤ 0.001) for ITU admission or death (41). The Saudi Arabian MERS outbreak in 2013 - 2014 exhibited a case fatality rate of 52% in men and 23% in women (42). Sex differences in both the innate and adaptive immune system have been previously reported and may account for the female advantage in COVID-19. Within the adaptive immune system, females have higher numbers of CD4+ T (43) (44) (45) (46) (47) (48) cells, more robust CD8+ T cell cytotoxic activity (49), and increased B cell production of immunoglobulin compared to males (43) (50). Female B cells also produce more antigen-specific IgG in response to TIV (51).

Age-related changes in the immune system are also different between sexes and there is a marked association between morbidity/mortality and advanced age in COVID-19 (52). For example, males show an age-related decline in B cells and a trend towards accelerated immune ageing. This may further contribute to the sex bias seen in COVID-19 (53).

Hence, this single center, retrospective, data oriented study performed to identify the gender age influences the RAT results and the rate of positive cases before and after the lockdown.

Methodology

This is a single-center, retrospective, data oriented study performed at the private hospital, Central Province, Sri Lanka. The data of the patients who performed the Rapid Antigen Test (RAT) from 11.08.2021to 11.0.2021 to know whether they have infected by SARS-CoV-2 or not, were taken for analysis. The authors developed a data extraction form on an Excel sheet and the following data from main data sheet. Test performed date, age, sex, number of positive and negative cases, number of female patients and number of male patients were extracted. Mistyping of data was resolved by crosschecking. Finally the data were analyzed in simple statistical method according to the objective of the study.

Results and discussion

Totally 642 patients performed RAT within the period of one month from 11.08.2021 to 11.09.2021. Among them 426 (66.35%) are male and 216 (33.64%) are female. Men mostly involved in several activities such as alcohol consumption, being involved in key activities during burial rites, and working in basic sectors and occupations that require them to continue being active, to work outside their homes and to interact with other people even during the containment phase. Therefore, men have increased level of exposure and high risk of getting COVID-19 (28) (29) (30). The present data descriptive study also were supported certain previous research findings.

The number of male patients got positive result in RAT among the total male patients who performed RAT on every day. According to that, 20.4% (n=131) of male obtained positive result among the total male population (n=426). Philip Goulder, professor of immunology at the University of Oxford stated that women’s immune response to the virus is stronger since they have two X chromosomes which is important when talk about the immune response against SARS-Cov-2. Because the protein by which viruses such as coronavirus are detected is fixed on the X chromosome. This is exactly looks like females have double protection compare to male. The present study also showed that large number of RAT positive cases were observed in males compare to females. Gender based lifestyle would have been another possibility for large number of males got positive in RATs. There are important behavioral differences between the sexes according to certain previous research findings (54).

Shows that the number of female patients got positive result in RAT among the total female patients who performed RAT on every day. According to that, 11.4% (n=73) of female obtained positive result among the total male population (n=216).

The relations between the number of positive cases before and after the lockdown. The lockdown declared by the tenth day from the initial day when the data was taken for analysis. The red vertical line differentiates the period as two such as before and after the lockdown. Though there was no decline observed as soon as immediately considerable decline was observed after the 21 days of onset of lockdown. Staying at home, avoiding physical contacts, and avoiding exposure in crowded areas are the best way to prevent the spread of Covid – 19 (54). However the significant decline would be able to see after three weeks only from the date of lockdown since the incubation period of SARS-CoV-2 is 14-21 days. The continuous study should be conducted in order to prove it. However the molecular mechanism of COVID-19 transmission pathway from human to human is still not resolved, the common transmission of respiratory diseases is droplet sprinkling. In this type of spreading, a sick person is exposed to this microbe to people around him by coughing or sneezing. Only the way to prevent these kind of respiratory diseases might be prevent the people to make close contact (54) (55). Approximately 214 countries reported the number of confirmed COVID-19 cases (56). Countries including Sri Lanka have taken very serious constraints such as announced vacation for schools, allowed the employers to work from home and etc. to slow down the COVID 19 outbreak. The lockdown days differ by countries. Countries have set the days when the lockdown started and ended according to the COVID-19 effect on their public. Some countries have extended the lockdown by many days due to COVID-19 continues its influence intensely on the public (57) (58).

The incidence of Covid-19 and age group. Accordingly large number was observed (34.89%) between the age group of 31-40 years in both sexes. The age group of 21-30 and 41-50 years also were shared the almost same percentage (17.13% & 17.75). A study provides evidence that the growing COVID-19 epidemics in the US in 2020 have been driven by adults aged 20 to 49 and, in particular, adults aged 35 to 49, before and after school reopening (59). However many researches pointed out that adults over the age of 60 years are more susceptible to infection since their immune system gradually loses its resiliency.

The relations between the positive number of male & female patients and the age group of total patients. According to that the large number of positive male patients observed among the age group of 41-50 years. Almost same number of patients was observed in the age group of 21-30 and 31-40. The least number of positive cases (0.7% and 0.9%) observed almost in 0-10 and 81-90 years. When considering the females, large number of positive female patients observed among the age group of 31-40 years. In USA Ministry of Health has reported 444 921 COVID-19 cases and 15 756 deaths as of August 31. For men, most reported cases were persons aged 30–39 years (22.7%), followed by 20–29 year-olds (20.1%) and 40–49 year-olds (17.1%). Most reported deaths were seniors, especially 70–79 year-olds (29.5%), followed by those aged 80 years and older (29.2%), and 60–69 year-olds (22.8%). Also found a similar pattern for women, except that most deaths were reported among women aged 80 years and older (44.4%) (60).

Conclusion

The present study showed that the male are mostly got positive in RAT test than female. Further comparing the old age young age group in both sexes were noticed as positive in RAT. Moreover there were no relationship observed before and after the lockdown and trend of Covid-19

 The limitations of the study

This study has several limitations.

Only 1 hospital was studied.

More than the absence of specific data on mobility patterns or transportation, detail of recovery, detail of mortality etc.

The COVID-19 pandemic is still ongoing so statistical analysis should continue. There are conflicting statements regarding lockdown by countries on COVID-19.

The effect of the lockdown caused by the COVID-19 pandemic on human health may be the subject of future work.

[p0ison-moon]

Chicago tribune wants you to pay to read that article, and it’s not on archive.org, so I went and paid for a subscription which I’m going to cancel tomorrow because fuck that.

anyways, below the cut:

Prediabetes: The epidemic that never was, and shouldn’t be

By Hank Campbell and Isabel Beshar

July 29, 2016 at 4:53 p.m.

This summer, your TV will begin alerting you to the dangers of high blood sugar. Your phone will buzz with automatic messages assessing the glycemic index of your breakfast bagel. And your Facebook feed will remind you to take the stairs, not the elevator.

This is all the result of a recent initiative intended to increase awareness of a condition known as prediabetes.

Marked by abnormal but not yet pathological blood sugar levels, prediabetes acts as a risk marker for Type 2 diabetes, a metabolic disease in which the body fails to properly process sugar. The idea is akin to cancer prevention: catch the tumor early (prediabetes) and avoid metastasis (diabetes). According to the most recent Centers for Disease Control and Prevention numbers, prediabetes is becoming a national emergency. In 2014, 86 million adult Americans were said to be prediabetic.

This means that 1 in 3 American adults have prediabetes — a figure higher than the number of Americans who currently hold a bachelor’s degree.

Yet those claims may be scaring more people than they are helping. The United States has the lowest prediabetes cut-off points of high-income countries around the world, meaning that prediabetes gets diagnosed earlier and more frequently, leading to new patients and higher costs. In 2003, and then again in 2010, the American Diabetes Association shifted the prediabetes diagnostic threshold down, from 110 to 100 milligrams per deciliter for the finger-stick glucose test, and from 6.0 to 5.7 percent for the average blood sugar level (the HbA1C test).

Other countries have pushed back. So has the World Health Organization, which has cautioned since 2006 that lower thresholds would needlessly double the prevalence of prediabetes and inadvertently implicate patients at minimal or no risk. In China, for example, adoption of the current ADA guidelines would result in 493 million new prediabetics.

It’s also unclear if the predictive value of prediabetes is actually valuable. The most recent long-term epidemiological surveys show that only 5 to 10 percent of patients labeled prediabetic actually progress to diabetes, with a full 50 percent of people reverting to normal glycemia in follow-up visits. This may be why the WHO and International Diabetes Federation have effectively de-adopted the “prediabetes” lexicon, noting that “so many people do not progress to diabetes as the term implies.”

Lowering the diagnostic threshold has clear economic implications. It’s a gold mine for the pharmaceutical industry, thanks to the American Association of Clinical Endocrinologists’ recommendation that diabetes drugs be used in patients with prediabetes. More diagnoses mean more sales, even though pharmaceutical interventions rarely work for prediabetes and their side effects are well reported.

It’s already the case that a staggering $322 billion is spent annually caring for people with prediabetes and diabetes.

In medical anthropology, this phenomenon is known as “medicalization” — the process by which normal bodily functions, characteristics or metrics become pathologized. This has been the case in public health rhetoric about menopause, aging and, more recently, high blood pressure.

It is normal — indeed, it is statistically likely — to have blood sugars that temporarily read in the prediabetes category. On your period? Had a happy hour cocktail? Stressed? Your blood sugar can spike or drop by as much as 20 mg/dL hourly. But head to the doctor on these days, and you walk away with a scary diagnosis, a costly prescription for a drug that may not even help you and seemingly unattainable lifestyle changes.

Diabetes is a serious and life-altering disease. In the eye of its storm, we are in desperate need of strategies to cope with it. But increasing the scope of the precondition is not necessarily the answer. We need to focus our attention and treat those who are suffering — not carelessly widen our lens.

Isabel Beshar is a 2014 Rhodes scholar and a candidate for a postgraduate degree in medical anthropology at the University of Oxford. Hank Campbell is president of the American Council on Science and Health.

I saw a comment on your blog that says 'the way you eat does not cause diabetes'...are you able to expand on that or provide a source I could read? I've been told by doctors that my pre-diabetes was due to weight gain because I get more hungry on my anti psychotics and I'd like to fact check what they've told me! Thank you so much!

Pre-diabetes was rejected as a diagnosis by the World Health Organization (although it is used by the US and UK) - the correct term for the condition is impaired glucose tolerance. Approximately 2% of people with "pre-diabetes" go on to develop diabetes per year. You heard that right - TWO PERCENT. Most diabetics actually skip the pre-diabetic phase.

There are currently no treatments for pre-diabetes besides intentional weight loss. (Hmm, that's convenient, right?) There has yet to be evidence that losing weight prevents progression from pre-diabetes to T2DM beyond a year. Interestingly, drug companies are trying to persuade the medical world to start treating patients earlier and earlier. They are using the term “pre-diabetes” to sell their drugs (including Wegovy, a weight-loss drug). Surgeons are using it to sell weight loss surgery. Everyone’s a winner, right? Not patients. Especially fat patients.

Check out these articles:

Prediabetes: The epidemic that never was, and shouldn’t be

The war on ‘prediabetes' could be a boon for pharma—but is it good medicine?

Also - I love what Dr. Asher Larmie @fatdoctorUK has to say about T2DM and insulin resistance, so here's one of their threads I pulled from Twitter:

1️⃣ You can't prevent insulin resistance. It's coded in your DNA. It may be impacted by your environment. Studies have shown it has nothing to do with your BMI.

2️⃣ The term "pre-diabetes" is a PR stunt. The correct term is impaired glucose tolerance (or impaired fasting glucose) which is sometimes referred to as intermittent hyperglycemia. It does not predict T2DM. It is best ignored and tested for every 3-5yrs.

3️⃣ there is no evidence that losing weight prevents diabetes. That's because you can't reverse insulin resistance. You can possibly postpone it by 2yrs? Furthermore there is evidence that those who are fat at the time of diagnosis fair much better than those who are thin.

4️⃣ Weight loss does not reverse diabetes in the VAST majority of people. Those that do reverse it are usually thinner with recent onset T2DM and a low A1c. Only a tiny minority can sustain that over 2yrs. Weight loss does not improve A1c levels beyond 2 yrs either.

5️⃣ Weight loss in T2DM does not improve macrovascular or microvascular health outcomes beyond 2 years. In fact, weight loss in diabetics is associated with increased mortality and morbidity (although it is not clear why). Weight cycling is known to impacts A1c levels.

6️⃣ Weight GAIN does NOT increase the risk of cardiovascular OR all causes mortality in diabetics. In fact, one might even go so far as to say that it's better to be fat and diabetic than to be thin and diabetic.

Dr. Larmie cites 18 peer reviewed journal articles (most from the last decade) that are included in their webinar on the subject, linked below.

[health-views-updates]

Preeclampsia Diagnostics Market Size and Share: Demand Forecast to 2032

The Preeclampsia Diagnostics Market Revenue was valued at USD 1.08 billion in 2023 and is anticipated to reach USD 1.33 billion by 2031, exhibiting a modest but steady CAGR of 2.7% during the forecast period from 2024 to 2031. The rising prevalence of preeclampsia and other hypertensive disorders in pregnancy, coupled with increasing awareness regarding early diagnosis, are key factors driving market growth.

Key Market Drivers

Preeclampsia, a pregnancy-related hypertensive disorder, remains a leading cause of maternal and fetal morbidity and mortality worldwide. The growing emphasis on maternal health and advancements in diagnostic technologies are bolstering the demand for preeclampsia diagnostics. Healthcare providers are focusing on early and accurate detection to mitigate risks, reduce complications, and improve outcomes for both mothers and babies.

The market is also witnessing increased adoption of biomarker-based diagnostic tests, which provide enhanced sensitivity and specificity for early-stage detection. In addition, rising government initiatives and investments in healthcare infrastructure, particularly in emerging economies, are further fueling the demand for innovative diagnostic solutions.

Regional Insights

North America dominates the preeclampsia diagnostics market, attributed to well-established healthcare systems, robust R&D activities, and high awareness among healthcare professionals. Europe follows closely, supported by favorable government policies and a growing focus on women's health. Meanwhile, the Asia-Pacific region is expected to experience significant growth due to rising healthcare expenditures, increasing pregnancy complications, and the expanding availability of diagnostic facilities.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/2993

Market Outlook

As healthcare technologies continue to evolve, the integration of point-of-care testing devices and artificial intelligence (AI) in diagnostics is transforming the preeclampsia diagnostics market. These advancements not only improve diagnostic accuracy but also enhance accessibility in remote and underserved areas. Partnerships between technology providers and healthcare organizations are fostering the development of innovative and cost-effective solutions, paving the way for sustainable growth in the coming years.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[global-research-report]

Europe Animal Health Market Analysis: Growth Drivers and Emerging Innovations

The Europe animal health market size was estimated at USD 16.5 billion in 2023 and it is projected to grow at a CAGR of 8.0% from 2024 to 2030. An increase in the number of pet owners, growing pet humanization, unceasing demand for meat and milk leading to a rise in livestock population, increase in the expenditure on veterinary medicines and other animal health products, growing awareness about animal welfare, government initiatives directed toward the wellbeing of animals, and growing availability of animal health solutions have driven the market growth in Europe.

Europe’s animal health market accounted for a 26.5% share (second-largest) of the global animal health industry in 2023. In recent years, the total population of production and companion animals has been on the rise. According to the FEDIAF 2023 report, 91 million households in the European Union region own a pet (46%), with around 127 million cats, 104 million dogs, and other pets. This population develops a huge demand for all sorts of animal health products including biologics, pharmaceuticals, diagnostics, equipment & disposables, medicinal feed activities, and other health-related solutions.

Europe Animal Health Market Segmentation

Pharmaceuticals led the market with the largest revenue share of 43.8% in 2023. Offerings such as parasiticides, anti-infective products, anti-inflammatory products, and analgesics are some of the pharmaceutical products used for animal health.

The production animals segment dominated the market with the largest revenue share of 65.7% in 2023. The global livestock population has been growing unceasingly and Europe holds a large share of this number.

Based on end-use, veterinary hospitals & clinics led the market with the largest revenue share of 72.1% in 2023. The point-of-care testing/in-house testing segment is projected to grow at a CAGR of 12.4% from 2024 to 2030.

The Poland animal health market is expected to experience a CAGR of 10.6% from 2024 to 2030. This growth can be attributed to a variety of drivers such as high milk consumption and dairy farming in the country, enhancements in economic conditions, and growing inclination of researchers to conduct clinical trials for animal health products.

Europe Animal Health Market Report Segmentation

This report forecasts revenue growth at a regional and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe animal health market report based on product, animal type, end-use, distribution channel and country.

Product Outlook (Revenue, USD Billion, 2018 - 2030)

Biologics

Vaccines

Modified/ Attenuated Live

Inactivated (Killed)

Other Vaccines

Other Biologics

Pharmaceuticals

Parasiticides

Anti-infectives

Anti-inflammatory

Analgesics

Others

Medicinal Feed Additives

Diagnostics

Consumables, reagents and kits

Instruments and devices

Equipment & Disposables

Critical Care Consumables

Anesthesia Equipment

Fluid Management Equipment

Temperature Management Equipment

Rescue & Resuscitation Equipment

Research Equipment

Patient Monitoring Equipment

Others

Veterinary Telehealth

Veterinary Software

Livestock Monitoring

Animal Type Outlook (Revenue, USD Billion, 2018 - 2030)

Production Animals

Poultry

Swine

Cattle

Sheep & Goats

Fish

Companion Animals

Dogs

Cats

Horses

Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

Veterinary Reference Laboratories

Point-of-care Testing/In-house Testing

Veterinary Hospitals & Clinics

Others

Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

Retail

E-Commerce

Hospital/ Clinic Pharmacy

Country Outlook (Revenue, USD Billion, 2018 - 2030)

Germany

France

Italy

Spain

Switzerland

Netherlands

Russia

Sweden

UK

Poland

Ireland

Order a free sample PDF of the Europe Animal Health Market Intelligence Study, published by Grand View Research.

[healthcarediagnosticmarket]

Paper Diagnostics Market Future Growth Insights: Trends and Innovations , Business Insights, Revenue and Forecast from 2024-2033

Straits Research: Paper Diagnostics Market Poised for Significant Growth, Projected to Reach USD 16.17 Billion by 2030

New York, NY - December 17, 2024 – The global paper diagnostics market, valued at USD 8 billion in 2021, is on a steady trajectory of growth and is projected to reach USD 16.17 billion by 2030, growing at a robust Compound Annual Growth Rate (CAGR) of 8.13% during the forecast period (2022–2030), according to a new market research report by Straits Research.

The market for paper diagnostics has witnessed an exponential rise due to its increasing adoption in healthcare, environmental monitoring, and food safety. These diagnostics are cost-effective, easy to use, and require minimal technical expertise, making them ideal for a wide range of applications across different industries.

Market Definition Paper diagnostics refers to diagnostic tools that use paper-based materials, microfluidics, and lateral flow assays to conduct medical tests and analyses. These devices are used for monitoring, diagnosing, and testing various health conditions, environmental parameters, and food quality, offering significant advancements in convenience and efficiency.

Key Trends Shaping the Paper Diagnostics Market

Advancement in Paper-based Microfluidics: The development of paper-based microfluidics is rapidly evolving, offering precision diagnostics with reduced cost and time, which is driving the market’s expansion.

Rise in Point-of-Care Diagnostics: The growing preference for point-of-care (POC) diagnostic solutions is enabling the widespread use of paper diagnostics in both clinical and home settings, further enhancing market demand.

Market Drivers

Rising Prevalence of Chronic Diseases: With the increasing burden of chronic diseases like cancer, liver disorders, and infectious diseases, there is a growing need for affordable, easy-to-use diagnostic tools, thereby driving market growth.

Growing Demand for Home Healthcare: The shift toward home healthcare and self-testing solutions, especially post-pandemic, is fueling the adoption of paper diagnostics.

Market Opportunities

Expansion in Developing Regions: The rapid development of healthcare infrastructure and growing awareness of diagnostic solutions in emerging markets like Asia-Pacific provides significant growth opportunities.

Technological Innovations: Ongoing innovations in paper diagnostics, such as the integration of artificial intelligence and machine learning, could lead to more advanced, accurate, and efficient diagnostic tools.

Market Segmentation The global paper diagnostics market is segmented based on type, product, application, and end-user. The detailed segmentation is as follows:

By Type

Monitoring Devices

Diagnostic Devices

By Product

Dipsticks

Lateral Flow Assays

Paper-Based Microfluidics

By Application

Environmental Monitoring

Clinical Diagnostics

Cancer

Infectious Diseases

Liver Disorders

Others

Food Quality Testing

By End-User

Home Healthcare

Hospitals and Clinics

Assisted Living Healthcare Facilities

For more information on detailed segmentation, please visit this link.

Key Market Players Several leading companies dominate the paper diagnostics market. These include:

Abbott

Bio-Rad Laboratories

Siemens Healthcare Gmbh

Abcam Plc

Chembio Diagnostic Systems Inc.

Acon Laboratories Inc.

FFEI

ARKRAY Inc.

Creative Diagnostics

Regional Insights North America is currently the dominant region in the paper diagnostics market, owing to advanced healthcare systems and early adoption of innovative diagnostic technologies. However, Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by increasing healthcare investments and a growing demand for affordable diagnostic solutions.

Conclusion The paper diagnostics market is experiencing strong growth, driven by the demand for affordable, efficient, and easy-to-use diagnostic solutions across healthcare, environmental monitoring, and food safety sectors. With technological advancements and increasing awareness, the market is expected to continue its upward trajectory through 2030.

For more information or queries, or if you require customization before making a purchase, please visit here.

This press release highlights the promising future of the paper diagnostics market, detailing key trends, drivers, opportunities, and segmentation. The information is essential for stakeholders looking to understand the dynamics of the market and make informed decisions.

About Straits Research

Straits Research is dedicated to providing businesses with the highest quality market research services. With a team of experienced researchers and analysts, we strive to deliver insightful and actionable data that helps our clients make informed decisions about their industry and market. Our customized approach allows us to tailor our research to each client's specific needs and goals, ensuring that they receive the most relevant and valuable insights.

Contact Us

Email: sales@straitsresearch.com

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: UK: +44 203 695 0070, USA: +1 646 905 0080

[willyskristina]

Portable Ultrasound Market

Portable Ultrasound Market Size, Share, Trends: General Electric Company (GE Healthcare) Leads

Integration of Artificial Intelligence and Cloud-Based Solutions in Portable Ultrasound Devices

Market Overview:

The global portable ultrasound market is expected to develop at a CAGR of XX% between 2024 and 2031. The market will grow from USD XX billion in 2024 to USD YY billion by 2031. North America now dominates the market, accounting for the vast majority of worldwide sales. Key metrics include rising acceptance of point-of-care diagnostics, technological breakthroughs in portable ultrasound devices, and increased demand for low-cost imaging solutions.

The portable ultrasonography market is expanding rapidly, owing to an increased demand for quick and accurate diagnostic instruments in a variety of healthcare settings. Miniaturisation and image quality advancements are improving the capabilities of portable ultrasound devices, broadening their applications across numerous medical specialities.

DOWNLOAD FREE SAMPLE

Market Trends:

The portable ultrasound industry is seeing a considerable increase in the integration of artificial intelligence (AI) and cloud-based technologies. These cutting-edge innovations expand the capabilities of portable ultrasound machines, improve image quality, and streamline operational operations. AI algorithms are being used to help with image interpretation, reduce operator dependency, and provide real-time coaching during exams. Deep learning systems, for example, can recognise and measure anatomical components automatically, thereby boosting diagnosis accuracy while reducing examination time. Cloud-based systems allow for remote storage, sharing, and analysis of ultrasound images, facilitating telemedicine applications and collaborative diagnosis. The growing desire for more efficient and reliable diagnostic tools in resource-constrained settings, as well as the necessity for seamless integration with hospital information systems, are driving this development. Major ultrasound manufacturers are making significant investments in AI and cloud technologies, resulting in a new generation of smart portable ultrasound devices with improved functionality and connection.

Market Segmentation:

The handheld ultrasound category has the highest market share in the portable ultrasound industry. These tiny devices enable unprecedented portability, allowing healthcare personnel to do ultrasound tests in a variety of situations, including emergency rooms and rural clinics. Handheld ultrasound devices have grown in popularity across a wide range of medical specialities due to their ease and versatility.

Recent developments in handheld ultrasound technology have strengthened its market dominance. For example, the emergence of wireless probes and smartphone-compatible ultrasound instruments have broadened the scope of mobile diagnostics. Research published in the Journal of the American College of Cardiology found that cardiologists' use of pocket-sized ultrasound equipment resulted in changes in patient management in 35% of cases, underscoring their clinical significance. Radiology is driving tremendous growth in the handheld ultrasound industry. The American College of Radiology reported that the use of handheld ultrasound equipment in radiology departments increased by 50% between 2019 and 2023. These devices are especially useful for bedside inspections, interventional treatments, and emergency situations where quick imaging is required.

Market Key Players:

General Electric Company (GE Healthcare)

Koninklijke Philips N.V.

Siemens Healthineers AG

Canon Medical Systems Corporation

Fujifilm Holdings Corporation

Samsung Electronics Co., Ltd. (Samsung Medison)

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[jameswilliam4u]

Global Clinical Diagnostics Market Share, Size, Trends, Outlook, Growth & Forecast | 2024 - 2032

The global clinical diagnostics market reached a value of over USD 72.23 billion in 2023, with expectations of further growth during the forecast period of 2024-2032. The market is anticipated to grow at a CAGR of around 6.7%, potentially reaching over USD 129.84 billion by 2032. This market encompasses a wide range of diagnostic tests, devices, and tools used in healthcare settings, and its expansion is driven by advancements in technology, increasing healthcare awareness, and rising demand for accurate and timely diagnostic solutions.

The clinical diagnostics sector is essential in diagnosing, monitoring, and managing diseases across different medical disciplines, such as oncology, cardiology, microbiology, and immunology. In this blog post, we will explore the key players, segments, trends, growth drivers, COVID-19 impact, and market outlook for the global clinical diagnostics market.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/clinical-diagnostics-market/requestsample

Key Players in the Clinical Diagnostics Market

The global clinical diagnostics market is highly competitive, with several established players leading the space. These companies continuously innovate and expand their product portfolios to meet the growing demand for advanced diagnostic solutions. Some of the major players in the market include:

Abbott Laboratories Abbott, headquartered in Chicago, Illinois, is a global healthcare company known for its diagnostic solutions, including point-of-care testing, molecular diagnostics, and immunoassays. Abbott has been at the forefront of developing COVID-19 testing solutions and expanding its diagnostic capabilities.

Thermo Fisher Scientific Based in Waltham, Massachusetts, Thermo Fisher Scientific is a leading player in the clinical diagnostics market, providing a broad range of diagnostic equipment, reagents, and testing systems. Their offerings include molecular diagnostics, clinical chemistry, and immunoassays.

Siemens Healthineers Siemens Healthineers, a division of Siemens AG, is headquartered in Erlangen, Germany. The company provides advanced diagnostic imaging, laboratory diagnostics, and point-of-care testing solutions. Their extensive product portfolio caters to diverse diagnostic needs across multiple medical fields.

Roche Diagnostics Roche, based in Basel, Switzerland, is a major player in the clinical diagnostics market, with a comprehensive range of diagnostic tests and systems. Roche offers solutions in molecular diagnostics, immunodiagnostics, and digital diagnostics, with a strong presence in oncology and infectious diseases.

Danaher Corporation Headquartered in Washington, D.C., Danaher is a leading provider of diagnostic tools and instruments. The company has a diversified portfolio that includes molecular diagnostics, immunodiagnostics, and clinical chemistry. Danaher’s brands, such as Beckman Coulter and Cepheid, are well-recognised in the industry.

Becton, Dickinson and Company (BD) BD, based in Franklin Lakes, New Jersey, is a global medical technology company that offers diagnostic products for clinical laboratories. BD's product range includes instruments, reagents, and consumables for microbiology, immunology, and hematology diagnostics.

Bio-Rad Laboratories Headquartered in Hercules, California, Bio-Rad Laboratories is a leader in life sciences and diagnostics. The company provides products for clinical diagnostics, including immunoassays, PCR tests, and blood typing solutions.

Market Segmentation

The clinical diagnostics market can be segmented based on product type, technology, application, end-users, and geography. Understanding these segments is crucial for identifying opportunities and analysing market trends.

By Product Type:

Instruments: This segment includes diagnostic machines and devices used in clinical laboratories and point-of-care settings, such as immunoassay analyzers, PCR machines, and clinical chemistry analyzers.

Reagents and Kits: Reagents and kits used for diagnostic testing are essential components of clinical diagnostics. These include immunoassay kits, PCR kits, and molecular diagnostics reagents.

Consumables: This includes the consumables required for diagnostic tests, such as test strips, blood glucose monitoring devices, and swabs.

By Technology:

Molecular Diagnostics: Molecular diagnostic tests involve the analysis of DNA, RNA, or proteins to identify diseases. Technologies such as PCR, next-generation sequencing, and microarrays are widely used in this category.

Immunoassays: These tests rely on antigen-antibody interactions to detect the presence of specific markers or pathogens, and they are commonly used in infectious disease diagnostics.

Clinical Chemistry: Clinical chemistry involves the analysis of blood, urine, and other bodily fluids to assess organ function and diagnose conditions like diabetes, liver disease, and kidney failure.

Hematology: Hematology tests focus on blood-related disorders, such as anemia, leukemia, and coagulation disorders. These tests often involve blood cell counting and analysis.

By Application:

Infectious Disease Diagnostics: This is one of the fastest-growing segments, driven by the rising prevalence of infectious diseases, including viral, bacterial, and parasitic infections.

Oncology Diagnostics: Early detection of cancers through molecular and imaging diagnostics is becoming increasingly important in oncology care.

Cardiovascular Diagnostics: The cardiovascular segment includes tests for heart disease, such as cholesterol testing, ECG, and blood pressure monitoring.

Diabetes Diagnostics: With the growing incidence of diabetes worldwide, diagnostic tests for blood glucose and insulin levels are in high demand.

Neurological Diagnostics: Tests for neurological diseases, including Alzheimer’s, Parkinson’s, and epilepsy, are becoming more sophisticated with advancements in imaging and biomarker detection.

By End-User:

Hospitals and Clinics: The largest segment in clinical diagnostics, hospitals and clinics rely heavily on diagnostic tests for patient care, treatment planning, and disease monitoring.

Diagnostic Laboratories: These laboratories focus on offering a wide range of diagnostic tests, including blood tests, imaging, and molecular diagnostics.

Home Care Settings: With the rise in at-home diagnostic tests, especially for diabetes and cardiovascular diseases, this segment is expected to witness significant growth.

Research Institutes: Research institutions conduct diagnostic tests for clinical trials and epidemiological studies.

Market Outlook and Growth Drivers

The global clinical diagnostics market is poised for substantial growth, driven by several key factors:

Technological Advancements: Advances in molecular diagnostics, artificial intelligence, and digital health are transforming clinical diagnostics. AI-powered diagnostic tools can assist clinicians in diagnosing diseases more accurately and faster.

Increased Healthcare Spending: The growing investment in healthcare infrastructure and diagnostic technologies, particularly in emerging economies, is expanding access to diagnostic services.

Rising Prevalence of Chronic Diseases: The global rise in chronic diseases, such as diabetes, cardiovascular diseases, and cancer, is fuelling demand for diagnostic tests to monitor and manage these conditions.

Aging Population: The increasing number of elderly individuals worldwide requires more diagnostic services for managing age-related conditions and chronic diseases.

Focus on Preventive Healthcare: There is a growing emphasis on early detection and preventive healthcare, which is driving the demand for diagnostic tests.

Trends in the Clinical Diagnostics Market

Point-of-Care Diagnostics: The demand for point-of-care diagnostic tests is increasing, as they offer rapid, on-site testing, particularly in emergency situations, rural areas, and home settings.

Molecular Diagnostics Growth: Molecular diagnostics, particularly PCR-based tests, are expected to grow significantly due to their accuracy and ability to detect genetic markers of diseases.

Integration of AI in Diagnostics: Artificial intelligence is being integrated into diagnostic devices to provide more accurate and faster results. AI can assist in interpreting medical images, analysing patient data, and offering real-time diagnostics.

Telemedicine and Remote Diagnostics: The growth of telemedicine is prompting the development of remote diagnostic tools that allow healthcare professionals to diagnose patients remotely.

COVID-19 Impact on the Clinical Diagnostics Market

The COVID-19 pandemic significantly impacted the clinical diagnostics market, especially in the initial phase, with increased demand for diagnostic tests to detect the virus. COVID-19 testing, including PCR tests and rapid antigen tests, saw a surge during the peak of the pandemic.

Although the pandemic led to some disruptions in diagnostic test production and distribution, it also accelerated the adoption of diagnostic innovations, such as home testing and digital diagnostics. The demand for accurate and quick diagnostics for viral infections has led to a shift towards more advanced and automated diagnostic solutions.

Post-pandemic, the market is expected to recover and continue its growth trajectory, with a focus on developing more sophisticated diagnostic solutions for future pandemics and disease outbreaks.

Frequently Asked Questions (FAQs)

What are the main drivers of growth in the clinical diagnostics market? The main drivers include technological advancements, increasing healthcare spending, the rising prevalence of chronic diseases, and the growing focus on preventive healthcare.

Which segment is expected to grow the fastest in the clinical diagnostics market? The molecular diagnostics segment is expected to grow rapidly due to advances in PCR testing, next-generation sequencing, and biomarker identification.

How has COVID-19 affected the clinical diagnostics market? COVID-19 significantly boosted demand for diagnostic tests, especially PCR and antigen tests. It also accelerated the adoption of telemedicine and remote diagnostics, which are expected to continue post-pandemic.

Who are the leading players in the clinical diagnostics market? Key players include Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Danaher Corporation, Becton Dickinson, and Bio-Rad Laboratories.

What is the market outlook for clinical diagnostics between 2024 and 2032? The global clinical diagnostics market is expected to grow at a CAGR of 6.7% during the forecast period, reaching a value of over USD 129.84 billion by 2032.

[mordorintelligencemarketresearch]

The Clinical Decision Support Systems (CDSS) Industry: Current Trends and Future Outlook

Market Overview

The global Clinical Decision Support Systems market is growing at an impressive pace. According to market research reports, the CDSS market size was valued at USD 2.2 billion in 2023 and is expected to reach USD 5.4 billion by 2030, growing at a compound annual growth rate (CAGR) of around 13.7% during the forecast period. This growth is attributed to several factors, including:

Increasing Healthcare Data: The rise of electronic health records (EHR) and the expansion of healthcare data have created an environment in which clinical decisions can be better informed by data-driven insights.

Rising Demand for Personalized Medicine: As healthcare moves towards more personalized treatment plans, CDSS tools that incorporate genomics and patient-specific data are gaining traction.

Cost Management and Efficiency: Healthcare organizations are under immense pressure to reduce costs while maintaining high standards of care. CDSS systems play a critical role in improving diagnostic accuracy, preventing medical errors, and reducing hospital readmissions, all of which contribute to cost savings.

Advancements in AI and Machine Learning: Machine learning and AI have enhanced the capability of CDSS to make accurate predictions, detect early signs of disease, and automate routine tasks. These technologies are making CDSS more sophisticated, predictive, and adaptive, resulting in greater accuracy in decision-making.

Regulatory Support: Governments and healthcare regulators are increasingly promoting the adoption of electronic health technologies, including CDSS, as part of efforts to modernize healthcare systems and improve patient outcomes.

Key Drivers and Trends in the CDSS Market

Integration with EHR Systems: One of the most significant trends in the market is the integration of CDSS with Electronic Health Records (EHR). This integration enables clinicians to access both clinical data and decision support tools in real time, streamlining workflows and improving efficiency.

Artificial Intelligence (AI) and Machine Learning: AI is transforming CDSS, particularly in areas such as predictive analytics, image recognition, and decision-making. AI-powered CDSS can analyze vast amounts of clinical data, identify patterns, and predict potential health risks, making clinical decision-making more precise.

Clinical Workflow Optimization: Modern CDSS tools are designed to seamlessly integrate into clinicians' daily workflows. With an intuitive user interface and the ability to provide real-time feedback, CDSS is becoming an integral part of healthcare delivery rather than an add-on tool.

Point-of-Care Applications: The demand for CDSS at the point of care is growing. These systems are now used in clinical settings to assist doctors, nurses, and other healthcare professionals in making real-time decisions at the patient's bedside, during diagnosis, or treatment planning.

Patient Empowerment: With the rise of patient-centric care, some CDSS applications are being developed to engage patients directly. These systems provide patients with insights into their own health conditions, empowering them to make informed decisions about their treatment plans.

Challenges Facing the CDSS Industry

Despite the impressive growth and promise of Clinical Decision Support Systems, there are several challenges that the industry must overcome:

Data Privacy and Security: As CDSS relies on sensitive health data, ensuring the privacy and security of patient information is a top priority. Healthcare organizations must adhere to strict regulatory standards, such as HIPAA (Health Insurance Portability and Accountability Act), to protect patient data.

Clinical Adoption and Trust: Although CDSS systems are highly effective, many clinicians are still hesitant to fully adopt these technologies. Resistance may stem from concerns about the accuracy of recommendations, potential disruptions to workflow, or lack of trust in automated systems.

Integration with Legacy Systems: Many healthcare organizations still rely on older IT infrastructure and EHR systems, which can be challenging to integrate with modern CDSS tools. Seamless interoperability between new and old systems is essential for CDSS success.

Regulatory Compliance: The healthcare industry is heavily regulated, and CDSS solutions must comply with various guidelines and standards. Developers must ensure their products meet regulatory requirements and are capable of adapting to evolving healthcare laws.

Quality of Data: The quality of input data directly affects the performance of CDSS systems. Ensuring that data is accurate, up-to-date, and comprehensive is essential for effective decision-making.

Future Outlook for the CDSS Market

The future of the Clinical Decision Support Systems industry looks promising, driven by continuous advancements in AI, data analytics, and healthcare technologies. Some key trends that will shape the future of the CDSS market include:

Expansion into Emerging Markets: As healthcare infrastructure improves in emerging markets, the adoption of CDSS is expected to rise, offering significant growth opportunities for industry players.

Personalized Medicine: With the integration of genomic data and individual patient profiles, CDSS will become even more customized, paving the way for precision medicine that tailors treatments to the specific needs of each patient.

Voice and Natural Language Processing (NLP): Voice-based interactions and NLP technologies will enable clinicians to use CDSS more intuitively, reducing the learning curve and improving user experience.

Remote Monitoring and Telemedicine: As telemedicine becomes increasingly mainstream, CDSS will play a critical role in providing remote support to clinicians making decisions about virtual patient care.

Conclusion

The Clinical Decision Support Systems market is poised for significant growth as healthcare continues to embrace digital transformation. With the integration of AI, machine learning, and data analytics, CDSS is evolving from a simple tool for information retrieval to a sophisticated assistant that improves clinical outcomes and enhances operational efficiency. As healthcare systems worldwide prioritize precision, efficiency, and patient-centered care, the role of CDSS will only become more prominent, making this an exciting time for both healthcare providers and technology developers alike.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence

[idigitizellp21]

The Impact and Prevalence of Misdiagnosis in HealthCare: Understanding Errors and Solutions

An accurate medical diagnosis is critical as it serves as the foundation for all subsequent healthcare decisions. However, when diagnosis errors occur, they can lead to a cascade of negative consequences affecting not just the individual patient, but also their families, the healthcare system, and society at large. Misdiagnosis is particularly prevalent in conditions like Alzheimer’s Disease (AD), where the label “Alzheimer’s” is more of a symptom cluster rather than a disease with a specific cause.

Types of Misdiagnosis in the health care industry:

Medical misdiagnoses are commonly categorised into three main types:

False-Positive Diagnoses: This occurs when a disease is diagnosed despite not being present. For instance, a patient may be diagnosed with cancer based on a test result that is later proven incorrect, leading to unnecessary treatments and emotional distress.

False-Negative Diagnoses: This type refers to the failure to detect an actual disease. A person may show clear symptoms of a serious condition like heart disease, but the diagnosis come back negative, delaying crucial treatment.

Equivocal Results: In some case, test results are inconclusive, leading to ambiguous diagnoses. The patient might receive a diagnosis that doesn’t definitively point to any specific disease, leaving them in limbo and without proper care.

Insufficient Depth of Diagnosis: Sometimes, diseases like Alzheimer’s are diagnosed based on limited perspectives, such as focusing solely on brain health. This narrow approach overlooks other potential causes or co-occuring conditions, resulting in an incomplete diagnosis.

The Cost of Misdiagnosis:

Misdiagnosis not only harms patients but also burdens the healthcare system. A 1997 survey by the National Patient Safety Foundation revealed that between 8% and 42% of patients reported misdiagnosis. One of the most common consequences of misdiagnosis is the failure to identify chronic conditions like diabetes or hypertension. While these conditions may not cause immediate harm, their long-term consequences can be sever if left untreated. Psychiatric diagnosis is particularly prone to errors, given the complex and often subjective nature of mental health conditions.

Mental Health and Cognitive Errors:

Studies on diagnostic errors in mental health suggest that cognitive biases significantly impact clinicians’s decision-making. For instance, checklists and brief educational interventions have shown to improve diagnostic accuracy in mental health assessments. However, even with these tools, the occurrence of diagnostic errors remains a persistent issue.

Advancing the Science of Diagnostic Safety:

Despite ongoing efforts to reduce diagnostic eros in healthcare, progress is hindered by the lack of clear definitions and measurements of diagnostic errors. More research is needed to understand preventable diagnostic opportunities, especially in mental health settings. Moving forward, it is crucial to integrate diagnostic safety into clinical practice and to develop tools that can help clinicians make more accurate diagnoses.

Misdiagnosis is a significant challenge in healthcare, affecting not only patient outcome but also the broader healthcare system. The ongoing research into diagnostic errors, particularly in mental health, offers hope for developing better tools and strategies to improve diagnostic accuracy. By advancing both the science and the practice of diagnosis, we can reduce errors and ensure better care for patients, ultimately leading to improved health outcomes and quality of life.

[health-views-updates]

2024-2032 Portable Ultrasound Market Demand & Revenue Growth Insights

The Portable Ultrasound Market Revenue was valued at USD 2678.60 million in 2023 and is projected to surge to USD 7481.55 million by 2031, growing at an impressive CAGR of 13.7% during the forecast period of 2024-2031. The rising demand for point-of-care diagnostics, increasing prevalence of chronic diseases, and advancements in ultrasound technology are driving significant growth in this market.

Key Drivers of Growth

Portable ultrasound devices are becoming increasingly popular due to their versatility, ease of use, and ability to provide real-time imaging. The healthcare sector's shift towards value-based care and the need for faster, more accurate diagnostics are further fueling the adoption of portable ultrasound systems across hospitals, clinics, and ambulatory care centers.

Technological advancements such as wireless connectivity, AI-powered imaging, and compact designs have expanded the applications of portable ultrasound devices in emergency care, critical care, and remote healthcare settings. These innovations are enabling healthcare providers to deliver high-quality diagnostics even in resource-limited environments, driving global market growth.

Regional Insights

North America leads the portable ultrasound market due to advanced healthcare infrastructure, high adoption of innovative medical technologies, and a significant focus on early disease detection. Meanwhile, the Asia-Pacific region is witnessing rapid growth, driven by increasing healthcare investments, rising awareness about portable diagnostic tools, and an expanding geriatric population.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/3091

Market Outlook

The portable ultrasound market is set to experience sustained growth as healthcare providers increasingly recognize the benefits of these devices in enhancing patient outcomes and reducing costs. The adoption of cloud-based solutions and telehealth integration is further expanding the market's potential, making portable ultrasound systems an essential tool for modern diagnostics.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[healthcarediagnosticmarket]

Therapeutic Drug Monitoring Market Strategic Trends: Insights, Healthy CAGR , Dynamic Innovation in Technology, Regional Outlook, Forecast to 2033

Global Therapeutic Drug Monitoring Market to Witness Robust Growth, Projected to Reach USD 5.0 Billion by 2032

Company Name: Straits Research Market Size: USD 2.0 Billion in 2023; projected to reach USD 5.0 Billion by 2032

New York, USA - December 17, 2024 – The global Therapeutic Drug Monitoring (TDM) Market was valued at USD 2.0 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 10.2%, reaching USD 2.3 billion in 2024 and USD 5.0 billion by 2032. This significant market growth is driven by the increasing prevalence of chronic diseases, advancements in healthcare technologies, and growing awareness of personalized medicine. The global TDM market is set to expand its presence as healthcare systems worldwide increasingly recognize the importance of measuring drug concentrations to optimize therapy.

Market Definition: Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in patients’ blood to ensure effective dosing, prevent toxicity, and enhance treatment outcomes. This practice is crucial for drugs with a narrow therapeutic index, where the difference between therapeutic and toxic levels is small. TDM is vital for drugs such as antiepileptic, antiarrhythmic, immunosuppressant, and antibiotic medications.

For a detailed understanding of the market dynamics, get a full PDF sample of the report at this link.

Market Dynamics:

Key Trends:

Integration of AI and Machine Learning in Drug Monitoring: The adoption of AI and machine learning technologies is transforming the TDM industry by enabling more accurate and efficient analysis of drug levels, predicting patient responses, and personalizing treatment.

Rising Focus on Personalized Medicine: With growing emphasis on precision medicine, TDM is playing an essential role in ensuring that patients receive tailored treatments based on their specific drug metabolism rates and response profiles.

Market Drivers:

Rising Prevalence of Chronic Diseases: Chronic diseases, such as epilepsy, heart disease, and autoimmune disorders, are contributing to the increased demand for TDM. These conditions often require long-term medication, making monitoring of drug levels essential to prevent adverse effects and ensure efficacy.

Advancements in Diagnostic Technologies: The development of advanced diagnostic tools and monitoring systems, such as immunoassays and chromatography-spectrometry, is driving market growth. These technologies enable faster, more accurate, and less invasive drug monitoring.

Market Opportunities:

Expansion in Emerging Markets: As healthcare infrastructure improves in emerging markets, there is a significant opportunity for TDM services and solutions to expand in regions like Asia-Pacific and Latin America.

Growing Adoption of Point-of-Care Testing: The increasing demand for point-of-care testing (POCT) devices offers substantial growth prospects for the TDM market, particularly in resource-limited settings where quick and accurate drug monitoring is crucial.

Market Segmentation:

By Technology:

Immunoassays

Chromatography-Spectrometry

By Product:

Consumables

Equipment

By Drug Class:

Antiepileptic Drugs

Antiarrhythmic Drugs

Immunosuppressant Drugs

Antibiotic Drugs

By End-User:

Hospitals

Diagnostic Labs

Research and Academic Institutes

For more information on market segmentation, visit here.

Key Players in the Therapeutic Drug Monitoring Market:

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

Danaher Corporation

Biomerieux SA

Chromsystems Instruments & Chemicals GmbH

SEKISUI CHEMICAL CO., LTD.

Bio-Rad Laboratories, Inc.

Exagen Inc.

Thermo Fisher Scientific Inc.

Siemens AG

Geographical Insights:

The North America region is currently dominating the TDM market due to its advanced healthcare infrastructure, high adoption rate of innovative diagnostic tools, and robust healthcare policies. However, the Asia-Pacific region is expected to witness the fastest growth, fueled by increasing healthcare investments, rising awareness, and growing demand for personalized medicine.

For more details, inquiries, or customization before purchasing the report, visit here.

About Straits Research: Straits Research is a leading market research and consulting firm specializing in providing comprehensive, actionable, and evidence-based insights to a diverse range of industries. With a focus on delivering high-quality research and strategic solutions, Straits Research empowers businesses to make informed decisions and achieve sustainable growth.

Contact Us

Email: sales@straitsresearch.com 

Address: 825 3rd Avenue, New York, NY, USA, 10022

Tel: +1 6464807505, +44 203 318 2846

[jcmarchi]

How AI-Led Platforms Are Transforming Business Intelligence and Decision-Making

New Post has been published on https://thedigitalinsider.com/how-ai-led-platforms-are-transforming-business-intelligence-and-decision-making/

How AI-Led Platforms Are Transforming Business Intelligence and Decision-Making

Imagine a retail company anticipating a surge in demand for specific products weeks before a seasonal shopping event. Or consider a healthcare provider accurately predicting patient influx during peak flu season, enabling them to allocate resources efficiently and improve care. These scenarios are not hypothetical—they are becoming the norm in organizations leveraging artificial intelligence (AI) for real-time, actionable insights.

AI is revolutionizing the way businesses strategize, make decisions, and maintain a competitive edge. As Deloitte’s “State of AI in the Enterprise” report reveals, 94% of business leaders view AI as essential for achieving success in the next five years. AI is no longer just a tool; it is a strategic enabler that high-performing organizations are leveraging to enter new markets, enhance products, and drive significant revenue growth.

This is where AI-led platforms come into play. Moving beyond traditional data processing, these platforms continuously analyze and interpret data from diverse sources, transforming it into intelligence that guides strategic actions in real-time. By integrating AI at the core of decision support, these platforms empower businesses to anticipate market shifts, adjust strategies, and respond swiftly to evolving conditions.

From Static Data to Real-Time Strategic Agility

AI-led platforms are a leap forward from static reporting and periodic insights. Today’s organizations need intelligence that continuously adapts to market shifts and consumer behaviors. According to McKinsey, by 2030, many companies will be approaching “data ubiquity,” where data is not only accessible but also embedded in every system, process, and decision point. This embedded data will drive automated, insight-driven actions with sufficient human oversight, allowing businesses to react to changes instantly and improve operational effectiveness.

For instance, healthcare organizations rely on AI-led platforms to predict patient needs with remarkable accuracy. These platforms analyze vast, real-time datasets from patient records, treatment histories, and diagnostic trends, enabling providers to optimize care delivery. By predicting patient inflow and aligning resources accordingly, healthcare institutions can improve outcomes and increase operational efficiency. This kind of agility is not just a benefit; it addresses the urgent demands of an industry that frequently operates under resource constraints, making healthcare delivery more adaptable and responsive.

Speeding Up Decision Cycles with AI-Driven Responsiveness

A core advantage of AI-led platforms is their ability to dramatically accelerate decision cycles, enabling organizations to respond to changes in real-time. Traditional business intelligence processes often involve time-consuming data collection, analysis, and interpretation, limiting an organization’s ability to act swiftly. In contrast, AI-led platforms provide continuous analysis, equipping leaders with data-backed insights that empower rapid, confident decision-making.

In retail, where customer preferences shift quickly, and demand can fluctuate hourly, AI-led platforms are invaluable. By continuously analyzing live data from sales, inventory, and customer interactions, these platforms allow retailers to dynamically adjust stock levels and adapt pricing strategies. According to a Deloitte report, by 2025, 20% of top global retailers are expected to achieve holistic results by using distributed AI systems. Additionally, 91% of executives identified AI as the most game-changing technology for retail in the next three years.

This responsiveness helps retailers minimize waste, avoid stockouts, and ensure products are available exactly when and where customers expect them. Such agility does not just meet immediate needs—it transforms retailers from reactive to proactive, allowing them to deliver exceptional customer experiences and operational efficiency in a competitive market.

Building Compounding AI Value Through Learning Systems

AI-led platforms do not merely provide static insights; they are self-learning systems that improve with each interaction. This ability to “learn” from past data and refine recommendations makes AI platforms more adept at predicting future outcomes, creating an ongoing cycle of improvement that helps organizations build resilience and foresight. By building compounding AI value, these platforms allow every successful decision to enhance future outcomes across interconnected areas of the business.

For financial services providers, this compounding value is transformative. Predictive models within AI-led platforms enable banks, investment firms, and insurers to identify and mitigate risks proactively. By recognizing emerging patterns in market data, these platforms help financial institutions adjust their strategies, make informed investment choices, and comply with regulatory requirements. This proactive approach safeguards their operations and enhances customer trust—a critical advantage in a sector where stability and trust are paramount. Over time, this cumulative learning leads to a stronger, more resilient organization equipped to navigate evolving financial landscapes with confidence.

Elevating Customer Engagement with Hyper-Personalized Intelligence

AI-led platforms are reshaping customer engagement by enabling unprecedented levels of personalization. Traditional customer segmentation methods are limited in scope, often categorizing customers into broad groups. AI, on the other hand, can deliver hyper-personalization by analyzing individual behaviors, preferences, and purchasing patterns. This enables businesses to provide experiences tailored to each customer’s unique needs, fostering stronger connections and driving loyalty.

Retailers, for example, are already harnessing the power of AI-led platforms to understand customer behavior in real-time. By analyzing data on previous purchases, browsing habits, and even location data, retailers can provide tailored product recommendations, exclusive promotions, and personalized reminders at optimal times. This level of engagement boosts immediate sales and builds lasting customer loyalty and brand affinity. In the competitive retail landscape, where customer expectations for personalization are constantly rising, such capabilities are becoming essential for long-term success.

Engineering Excellence and Optimizing for Scalability

To fully realize the potential of AI-led platforms, tech leaders must prioritize several strategic and operational imperatives. These include a commitment to engineering excellence, adaptability, scalability, and ethical transparency:

Precision in Model Development AI models are only as effective as the data and design behind them. Developing models that provide reliable, accurate insights demands rigorous attention to data quality, model training, and validation processes. Effective deployment also means ensuring that AI models can perform well in a wide range of real-world scenarios and adapt as new data comes in.

Modular and Adaptive Architectures Organizations benefit significantly from modular architectures that support rapid deployment and adapt to evolving needs. This flexibility enables tech teams to adjust components or integrate new capabilities without disrupting the entire platform. As market conditions change, this adaptive architecture becomes invaluable for maintaining relevance and responsiveness.

Optimizing for Scalability Beyond the Pilot Phase Many organizations struggle to move AI initiatives beyond the pilot stage. To truly capture AI’s value, it is essential to develop platforms that are scalable, robust, and consistent. Successful scaling requires platforms that can handle increased data volumes and user demands without compromising performance. Scalable solutions maximize the reach and impact of AI across the organization, ensuring predictable ROI and seamless transitions from experimentation to enterprise-wide deployment.

Deterministic Outcomes for Stability and Reliability As organizations rely on AI-led platforms to make critical, data-driven decisions, ensuring deterministic outcomes—consistent, predictable, and reliable results—becomes essential. Deterministic AI systems reduce the risk of unexpected behaviors or “hallucinations,” delivering accuracy and stability even as data volumes increase and environments shift. This predictability allows organizations to maintain confidence in AI-driven insights, crucial for supporting innovation without compromising operational stability.

Security and Ethical Transparency As AI systems gain access to sensitive data, particularly in sectors like healthcare and finance, security and ethical considerations become predominant. AI-led platforms must incorporate rigorous data governance, privacy measures, and ethical safeguards to operate transparently and responsibly. Building trust through transparent practices and a commitment to ethical standards is crucial for the successful adoption of AI-led systems in high-stakes industries.

Setting a New Standard for Decision Support and Competitive Foresight

The power of AI-led platforms lies not in doing things better, but in reshaping how businesses operate and compete. Future leaders will leverage AI for incremental gains and seize strategic opportunities others overlook, creating positions unique to AI-enabled enterprises.

These platforms allow businesses to build models that grow stronger with each decision, balancing human expertise with AI capabilities to deliver lasting value. By anticipating and proactively meeting customer needs, they foster loyalty and drive exponential growth.

For today’s leaders, the question is not how AI can improve decisions, but how it can redefine the game. Those who embrace AI as a foundation for sustainable growth will set the benchmarks for tomorrow—using platforms that continually innovate, adapt, and add value, positioning their organizations to lead in the future of intelligent business.

[jayanthitbrc]

Global DNA/RNA Sample Extraction And Isolation Market Analysis 2024: Size Forecast and Growth Prospects

The dna/rna sample extraction and isolation global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

DNA/RNA Sample Extraction And Isolation Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The DNA/RNA sample extraction and isolation market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to advancements in genomics research, increasing demand for personalized medicine, rising prevalence of genetic disorders, growing investments in life sciences research, technological advancements in sample extraction techniques.

The DNA/RNA sample extraction and isolation market size is expected to see strong growth in the next few years. It will grow to $3.3 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expanding applications of genomics in diagnostics and drug development, rising adoption of precision medicine, increasing awareness and focus on genetic testing, continuous developments in sample extraction technologies, growing collaborations and partnerships in the biotechnology sector. Major trends in the forecast period include technological advancements in extraction and isolation techniques, adoption of automation and high-throughput techniques, emergence of new players and collaborations in the market, shift towards point-of-care testing and decentralized diagnostics, rising investments in healthcare infrastructure and R&D.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/dna-or-rna-sample-extraction-and-isolation-global-market-report

Scope Of DNA/RNA Sample Extraction And Isolation Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

DNA/RNA Sample Extraction And Isolation Market Overview

Market Drivers - The rising prevalence of infectious diseases is expected to propel the growth of the DNA/RNA sample extraction and isolation market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. DNA/RNA extraction is essential for PCR-based diagnostic tests and is widely utilized to detect the genetic material of pathogens with sensitivity and specificity, enabling the identification of infectious agents like viruses or bacteria in patient samples. For instance, in July 2023, according to UNAIDS, a Switzerland-based UN program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Moreover, there were approximately 1.3 million new HIV infections reported in 2022. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,331 cases of tuberculosis (TB) were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the rising prevalence of infectious diseases will drive the growth of the DNA/RNA sample extraction and isolation market.

Market Trends - Major companies operating in the DNA/RNA sample extraction and isolation market are adopting new technologies, such as automated sample preparation and analysis solutions, to sustain their position in the market. An automated solution for sample preparation and analysis refers to a technology-driven system that streamlines and mechanizes the various steps involved in preparing samples and conducting analyses. For instance, in November 2023, Qiagen N.V., a Germany-based biotechnology and life sciences research company, launched the TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation. The introduction of two new products aims to support researchers in managing diverse materials such as bone, tissue, and soil samples. The TissueLyser III stands out as a high-throughput instrument adept at efficiently disrupting various biological samples containing nucleic acids, including DNA and RNA, offering enhanced versatility for researchers. In contrast, the RNeasy PowerMax Soil Pro Kit boasts a specialized design tailored to isolate high-purity RNA from difficult soil samples abundant in PCR inhibitors, leveraging QIAGEN's advanced inhibitor removal technology to overcome these challenges effectively.

The dna/rna sample extraction and isolation market covered in this report is segmented –

1) By Product: Consumables, Instruments 2) By Technology: Consumable-Based Technology, Instrument-Based Technology 3) By Application: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cloning, Microarray, Blotting Techniques, Other Applications 4) By End-User: Clinical Diagnostic And Forensic Laboratories, Research Academics And Institutions, Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CRO), Other End-Users

Get an inside scoop of the dna/rna sample extraction and isolation market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13842&type=smp

Regional Insights - North America was the largest region in the DNA/RNA sample extraction and isolation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna/rna sample extraction and isolation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - F Hoffmann-La Roche AG, Thermofisher Scientific Inc., Danaher Corporation , MilliporeSigma, Agilent Technologies, Illumina Inc., PerkinElmer Inc., Sigma-Aldrich, bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., Eppendorf AG, Macherey-Nagel Gmbh & Co. KG, Tecan Group, Promega Corporation, Abnova Corporation, Abcam Plc., Takara Bio Inc., New England Biolabs, Omega Bio-tek Inc., Zymo Research, PCR Biosystems, Biotium Inc., Beckman Coulter, Norgen Biotek Inc.

Table of Contents 1. Executive Summary 2. DNA/RNA Sample Extraction And Isolation Market Report Structure 3. DNA/RNA Sample Extraction And Isolation Market Trends And Strategies 4. DNA/RNA Sample Extraction And Isolation Market – Macro Economic Scenario 5. DNA/RNA Sample Extraction And Isolation Market Size And Growth ….. 27. DNA/RNA Sample Extraction And Isolation Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model